Why Hold SGLT2 Inhibitors Three Days Before Surgery
The primary reason to hold SGLT2 inhibitors 3 days before surgery is to reduce the risk of perioperative euglycemic diabetic ketoacidosis (DKA), a rare but potentially life-threatening complication that can occur even when blood glucose levels appear normal.
The Core Problem: Euglycemic Ketoacidosis
SGLT2 inhibitors increase urinary glucose excretion, which lowers blood glucose and shifts the insulin/glucagon ratio toward ketone production. When combined with surgical stress, fasting, and counterregulatory hormone release, this creates a perfect storm for ketoacidosis that can develop rapidly—even with normal glucose levels (< 11.0 mmol/L). Patients taking SGLT2 inhibitors have a 1.48-fold increased risk of perioperative DKA compared to those not taking them (1.02 vs. 0.69 per 1000 patients) 1.
The mechanism is straightforward: SGLT2 inhibitors promote ketogenesis by reducing glucose availability, and surgical stress amplifies this effect through increased cortisol, catecholamines, and glucagon release. The result can be ketone levels > 3.0 mmol/L and pH < 7.3—meeting DKA criteria—while glucose remains deceptively normal 1.
Why Specifically 3 Days?
The "3-day rule" is actually more nuanced than commonly practiced. The most recent 2025 multidisciplinary UK consensus guidelines recommend omitting SGLT2 inhibitors "the day before and the day of a procedure," which translates to a minimum 36-52 hour gap depending on timing 1. However, this represents a pragmatic compromise rather than an absolute safety threshold.
Here's the critical evidence:
- A review of nearly 100 perioperative DKA cases found that omitting SGLT2 inhibitors > 2 days preoperatively did NOT result in DKA 1
- However, case reports document ketoacidosis occurring even after > 72 hours of withholding, emphasizing that risk exists on a continuum 1
- One case series showed DKA developing 54-151 hours after the last dose, with one patient showing protracted drug effects at 7 days post-dose 2
The pharmacokinetic rationale: Most SGLT2 inhibitors have half-lives of 10-13 hours. Holding for 72 hours (approximately 5-7 half-lives) allows near-complete drug clearance under normal circumstances 3.
The Practical Algorithm
For elective surgery:
- Hold SGLT2 inhibitors at least 3 days (72 hours) before major surgery 2, 4, 3
- For morning procedures with morning dosing: minimum 48-52 hours is acceptable per UK guidelines 1
- For patients on very low-energy/liver reduction diets: stop at diet commencement (often 2-4 weeks preoperatively) 1
Risk factors requiring longer discontinuation or heightened vigilance:
- Insulin-dependent diabetes
- Poorly controlled diabetes
- Cardiac or renal disease requiring SGLT2 inhibitors for organ protection
- Major hepatic surgery (drug metabolism may be impaired) 5
- Prolonged anticipated fasting periods
Critical Caveats and Pitfalls
The euglycemic nature makes this dangerous. Traditional glucose monitoring will miss the problem. Blood glucose may be 5-10 mmol/L while ketones are critically elevated. This is why the condition is called "euglycemic" DKA and why it's so insidious 1.
Not just a diabetes problem. Recent reports document euglycemic DKA in patients WITHOUT diabetes taking SGLT2 inhibitors for heart failure or chronic kidney disease 1. The pathophysiology is identical—clinicians must remain vigilant regardless of diabetes status.
Emergency surgery presents a dilemma. When SGLT2 inhibitors cannot be held adequately, implement aggressive monitoring: check blood ketones every 6 hours for 24 hours postoperatively and until full oral diet resumes 3. Consider glucose-containing IV fluids even if blood glucose is normal to suppress ketogenesis 1.
The discontinuation paradox. Stopping SGLT2 inhibitors in heart failure patients may worsen cardiac function 1. Emerging data suggest perioperative discontinuation may actually increase cardiovascular complications—one study found adjusted odds ratio of 1.58 per discontinued day for cardiac events 6. This creates tension between preventing ketoacidosis and maintaining cardio-renal protection.
Mitigation Strategies During the Holding Period
While SGLT2 inhibitors are held:
- Ensure adequate hydration
- Avoid prolonged fasting (follow standard NPO guidelines, don't extend unnecessarily)
- Monitor ketones if high-risk (target < 0.6 mmol/L before restarting) 1
- Consider glucose-containing IV fluids for prolonged fasting scenarios
- Provide written sick-day rules at discharge 1
Restart only when: Patient is eating/drinking normally AND (for inpatients) capillary ketones < 0.6 mmol/L 1. This typically occurs 24-48 hours post-surgery for outpatients 1.
The Bottom Line
The 3-day holding period represents a balance between clearing the drug to minimize ketoacidosis risk while acknowledging that no duration guarantees complete safety. The risk is highest with emergency surgery (1.1% vs. 0.17% for elective) 1, insulin use, and prolonged fasting. Shared decision-making with patients about ketoacidosis risk, meticulous attention to hydration and fasting duration, and ketone monitoring in high-risk scenarios are as important as the holding period itself 1.